DOT Drug Test

DEA issued a narrow Schedule III order covering FDA-approved marijuana-related products and certain state-licensed medical marijuana activity. Here''s what changed, what didn''t, and what DOT drug testing programs need to know.

A federal order moved FDA-approved marijuana products to Schedule III. Here is what it changes for your DOT drug test program and what it does not.

The DEA placed FDA-approved marijuana products in Schedule III on April 28, 2026. Here is what the rule does, what it does not change for DOT drug testing, and what fleet managers should do now.

FAA published a Part 120 drug and alcohol testing program ICR renewal on April 24, 2026. Here is what the program covers, what the renewal asks for, and how it intersects with the broader DOT testing regime.

DOT just revised 49 CFR Part 40. When an oral fluid test is required but unavailable, collectors must conduct a directly observed urine collection. What every DOT D&A program operator needs to do.

DEA will hold a new hearing on the marijuana rescheduling rulemaking starting June 29, 2026. What DOT-regulated employers, drivers, and SAPs need to know about the testing implications.

The DEA withdrew the prior marijuana rescheduling hearing notice in April 2026 and set a new June 29 hearing. Find out what the procedural reset means for DOT drug test programs and CDL drivers.